CELC · Celcuity appointed David W

Celcuity appointed David W. Gryska, a seasoned life sciences CFO (Incyte, Celgene), to its Board of Directors, effective October 1, 2026. The appointment, announced alongside the commercial launch of its first FDA-approved product REVTORPYK, adds independent financial and strategic expertise to the board as the company transitions to a commercial-stage biotech. This is a routine board expansion with no material financial impact.

• David W. Gryska appointed to Celcuity's Board of Directors on October 1, 2026.
• Board size increased from 8 to 9 members.
• Gryska will serve on the Audit Committee and Compensation Committee.
• Gryska receives pro-rated director compensation: $70,000 annual cash retainer and $100,000 annual equity award.